Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: A collaborative project under COST Action BM0607

Luigi Aloj, Michela Aurilio, Valentina Rinaldi, Laura D'ambrosio, Diego Tesauro, Petra Kolenc Peitl, Theodosia Maina, Rosalba Mansi, Elisabeth Von Guggenberg, Lieke Joosten, Jane K. Sosabowski, Wouter A P Breeman, Erik De Blois, Stuart Koelewijn, Marleen Melis, Beatrice Waser, Karin Beetschen, Jean Claude Reubi, Marion De Jong

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COSTAction BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the presentstudy, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project. Methods Determination of IC50 values was performed using autoradiography, with DOTA-peptides displacing 125I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using 111In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (Kd) and apparent number of binding sites (Bmax) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C. Results All peptides showed high receptor affinity with IC50 values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with Kd values in the 10-9-10-8 M range. Bmax values estimated in A431- CCK2R cells ranged from 0.6 to 2.2×106 per cell. All peptides showed high levels of internalization when incubated at 37°C. Conclusion All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.

Original languageEnglish
Pages (from-to)1417-1425
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Cholecystokinin B Receptor
Peptides
Inhibitory Concentration 50
Cholecystokinin Receptors
Cell Line
Peptide Receptors
Neuroendocrine Tumors
Radiopharmaceuticals
indium-111-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
peptide A
European Union
Autoradiography
Radioisotopes
Neoplasms
Therapeutics
Binding Sites
Acids

Keywords

  • Cholecystokinin
  • DOTA
  • Gastrin
  • Tumour

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides : A collaborative project under COST Action BM0607. / Aloj, Luigi; Aurilio, Michela; Rinaldi, Valentina; D'ambrosio, Laura; Tesauro, Diego; Peitl, Petra Kolenc; Maina, Theodosia; Mansi, Rosalba; Von Guggenberg, Elisabeth; Joosten, Lieke; Sosabowski, Jane K.; Breeman, Wouter A P; De Blois, Erik; Koelewijn, Stuart; Melis, Marleen; Waser, Beatrice; Beetschen, Karin; Reubi, Jean Claude; De Jong, Marion.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 8, 08.2011, p. 1417-1425.

Research output: Contribution to journalArticle

Aloj, L, Aurilio, M, Rinaldi, V, D'ambrosio, L, Tesauro, D, Peitl, PK, Maina, T, Mansi, R, Von Guggenberg, E, Joosten, L, Sosabowski, JK, Breeman, WAP, De Blois, E, Koelewijn, S, Melis, M, Waser, B, Beetschen, K, Reubi, JC & De Jong, M 2011, 'Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: A collaborative project under COST Action BM0607', European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 8, pp. 1417-1425. https://doi.org/10.1007/s00259-011-1816-y
Aloj, Luigi ; Aurilio, Michela ; Rinaldi, Valentina ; D'ambrosio, Laura ; Tesauro, Diego ; Peitl, Petra Kolenc ; Maina, Theodosia ; Mansi, Rosalba ; Von Guggenberg, Elisabeth ; Joosten, Lieke ; Sosabowski, Jane K. ; Breeman, Wouter A P ; De Blois, Erik ; Koelewijn, Stuart ; Melis, Marleen ; Waser, Beatrice ; Beetschen, Karin ; Reubi, Jean Claude ; De Jong, Marion. / Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides : A collaborative project under COST Action BM0607. In: European Journal of Nuclear Medicine and Molecular Imaging. 2011 ; Vol. 38, No. 8. pp. 1417-1425.
@article{9da635affdf74c5aafc6f36de38c2740,
title = "Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: A collaborative project under COST Action BM0607",
abstract = "Purpose Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COSTAction BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the presentstudy, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project. Methods Determination of IC50 values was performed using autoradiography, with DOTA-peptides displacing 125I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using 111In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (Kd) and apparent number of binding sites (Bmax) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C. Results All peptides showed high receptor affinity with IC50 values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with Kd values in the 10-9-10-8 M range. Bmax values estimated in A431- CCK2R cells ranged from 0.6 to 2.2×106 per cell. All peptides showed high levels of internalization when incubated at 37°C. Conclusion All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.",
keywords = "Cholecystokinin, DOTA, Gastrin, Tumour",
author = "Luigi Aloj and Michela Aurilio and Valentina Rinaldi and Laura D'ambrosio and Diego Tesauro and Peitl, {Petra Kolenc} and Theodosia Maina and Rosalba Mansi and {Von Guggenberg}, Elisabeth and Lieke Joosten and Sosabowski, {Jane K.} and Breeman, {Wouter A P} and {De Blois}, Erik and Stuart Koelewijn and Marleen Melis and Beatrice Waser and Karin Beetschen and Reubi, {Jean Claude} and {De Jong}, Marion",
year = "2011",
month = "8",
doi = "10.1007/s00259-011-1816-y",
language = "English",
volume = "38",
pages = "1417--1425",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "8",

}

TY - JOUR

T1 - Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides

T2 - A collaborative project under COST Action BM0607

AU - Aloj, Luigi

AU - Aurilio, Michela

AU - Rinaldi, Valentina

AU - D'ambrosio, Laura

AU - Tesauro, Diego

AU - Peitl, Petra Kolenc

AU - Maina, Theodosia

AU - Mansi, Rosalba

AU - Von Guggenberg, Elisabeth

AU - Joosten, Lieke

AU - Sosabowski, Jane K.

AU - Breeman, Wouter A P

AU - De Blois, Erik

AU - Koelewijn, Stuart

AU - Melis, Marleen

AU - Waser, Beatrice

AU - Beetschen, Karin

AU - Reubi, Jean Claude

AU - De Jong, Marion

PY - 2011/8

Y1 - 2011/8

N2 - Purpose Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COSTAction BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the presentstudy, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project. Methods Determination of IC50 values was performed using autoradiography, with DOTA-peptides displacing 125I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using 111In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (Kd) and apparent number of binding sites (Bmax) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C. Results All peptides showed high receptor affinity with IC50 values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with Kd values in the 10-9-10-8 M range. Bmax values estimated in A431- CCK2R cells ranged from 0.6 to 2.2×106 per cell. All peptides showed high levels of internalization when incubated at 37°C. Conclusion All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.

AB - Purpose Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COSTAction BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the presentstudy, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project. Methods Determination of IC50 values was performed using autoradiography, with DOTA-peptides displacing 125I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using 111In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (Kd) and apparent number of binding sites (Bmax) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C. Results All peptides showed high receptor affinity with IC50 values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with Kd values in the 10-9-10-8 M range. Bmax values estimated in A431- CCK2R cells ranged from 0.6 to 2.2×106 per cell. All peptides showed high levels of internalization when incubated at 37°C. Conclusion All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.

KW - Cholecystokinin

KW - DOTA

KW - Gastrin

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=80052593793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052593793&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-1816-y

DO - 10.1007/s00259-011-1816-y

M3 - Article

C2 - 21523391

AN - SCOPUS:80052593793

VL - 38

SP - 1417

EP - 1425

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 8

ER -